Literature DB >> 11172682

Cytotoxic activity and inhibition of tumor cell invasion by derivatives of a chemically modified tetracycline CMT-3 (COL-3).

B L Lokeshwar1, E Escatel, B Zhu.   

Abstract

Tetracyclines such as chlortetracycline and doxycycline with antimicrobial activity were reported to possess cytostatic and cytotoxic activity against mammalian tumor cells, often at high doses. Non-antimicrobial chemically modified tetracyclines (CMTs), with limited systemic toxicity but with significant tumor cell toxicity and antimetastatic activity, are attractive for long term treatment for cancer. We recently reported one such CMT, 6-deoxy,6-demethyl 4-dedimethylamino tetracycline (CMT-3) is a potent anti-tumor and anti-metastatic drug. Here we report on the anti-cell proliferation and anti-invasive activity of five nitro derivatives of CMT-3 (CMT-3N). All the five CMT-3Ns (CMT-302, CMT-303, CMT-306, CMT-308 and CMT-316) inhibited in vitro cell proliferation of prostate cancer cells. The 50% growth inhibition concentration (IC(50)) of CMT-3Ns was similar to that of CMT-3. Although CMT-3 was by far the most potent anti-cell proliferation drug, all CMT-3Ns except CMT-303 and CMT-308 had similar anti-cell proliferation activity (IC(50): 2.5 -5.7 microg/ml). IC(50)s for CMT-303 and CMT-308 were approximately 8.1 and -12.4 microg/ml, respectively. Activity against tumor cell invasion was tested in vitro using the Matrigel invasion assay. All CMT-3Ns had similar anti- invasive activity. While cytotoxic activity of CMT-3 was strongly associated with cell death-effector caspase activation, mitochondrial permeablization and apoptosis, the CMT-3Ns weakly induced apoptosis and did not activate Caspase-3. However, the CMT-3Ns were able to induce mitochondrial permeabilization. This dichotomous mechanism of cytotoxic activity of CMTs may have significance in their selection for clinical application.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11172682     DOI: 10.2174/0929867013373516

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  11 in total

Review 1.  Chemically modified non-antimicrobial tetracyclines are multifunctional drugs against advanced cancers.

Authors:  Bal L Lokeshwar
Journal:  Pharmacol Res       Date:  2010-11-18       Impact factor: 7.658

2.  Quantitative characterization of binding of small molecules to extracellular matrix.

Authors:  Yufen Zhang; Viera Lukacova; Katie Reindl; Stefan Balaz
Journal:  J Biochem Biophys Methods       Date:  2006-02-17

3.  A chemically modified tetracycline (CMT-3) is a new antifungal agent.

Authors:  Yu Liu; Maria E Ryan; Hsi-Ming Lee; Sanford Simon; George Tortora; Carol Lauzon; Michael K Leung; Lorne M Golub
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

4.  Tetracyclines as Inhibitors of Pre-microRNA Maturation: A Disconnection between RNA Binding and Inhibition.

Authors:  Amanda L Garner; Daniel A Lorenz; Jorge Sandoval; Erin E Gallagher; Samuel A Kerk; Tanpreet Kaur; Arya Menon
Journal:  ACS Med Chem Lett       Date:  2019-04-22       Impact factor: 4.345

5.  The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth.

Authors:  Rajendra Kumar Singh; Bal L Lokeshwar
Journal:  Cancer Res       Date:  2011-03-11       Impact factor: 12.701

6.  Ericifolin: a novel antitumor compound from allspice that silences androgen receptor in prostate cancer.

Authors:  Nagarajarao Shamaladevi; Dominic A Lyn; Khaled A Shaaban; Lei Zhang; Susana Villate; Jürgen Rohr; Bal L Lokeshwar
Journal:  Carcinogenesis       Date:  2013-04-08       Impact factor: 4.944

Review 7.  Decoding and engineering tetracycline biosynthesis.

Authors:  Lauren B Pickens; Yi Tang
Journal:  Metab Eng       Date:  2008-10-22       Impact factor: 9.783

Review 8.  Clonal expansion of T cells in abdominal aortic aneurysm: a role for doxycycline as drug of choice?

Authors:  Albert M Kroon; Jan-Willem Taanman
Journal:  Int J Mol Sci       Date:  2015-05-18       Impact factor: 5.923

9.  Does doxycycline work in synergy with cisplatin and oxaliplatin in colorectal cancer?

Authors:  Jayesh Sagar; Kevin Sales; Sas Dijk; JanWillem Taanman; Alexander Seifalian; Mark Winslet
Journal:  World J Surg Oncol       Date:  2009-01-06       Impact factor: 2.754

10.  ATP7B Binds Ruthenium(II) p-Cymene Half-Sandwich Complexes: Role of Steric Hindrance and Ru-I Coordination in Rescuing the Sequestration.

Authors:  Kallol Purkait; Arindam Mukherjee; Arnab Gupta
Journal:  Inorg Chem       Date:  2019-10-28       Impact factor: 5.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.